ORF_ID	Contig	Start	Stop	Orientation	Cut_Off	Pass_Bitscore	Best_Hit_Bitscore	Best_Hit_ARO	Best_Identities	ARO	Model_type	SNPs_in_Best_Hit_ARO	Other_SNPs	Drug Class	Resistance Mechanism	AMR Gene Family	Predicted_DNA	Predicted_Protein	CARD_Protein_Sequence	Percentage Length of Reference Sequence	ID	Model_ID	Nudged	Note	Hit_Start	Hit_End	Antibiotic
BGC0000218.1|Doxorubicin_2 # 918 # 1865 # -1 # ID=1_2;partial=00;start_type=ATG;rbs_motif=AGGA;rbs_spacer=5-10bp;gc_cont=0.717	BGC0000218.1|Doxorubicin_2 	918	1865	-	Loose	600	26.1794	OprZ	37.5	3004142	protein homolog model	n/a	n/a	macrolide antibiotic; fluoroquinolone antibiotic; aminoglycoside antibiotic; cephalosporin	antibiotic efflux	resistance-nodulation-cell division (RND) antibiotic efflux pump	ATGTCCGAGTTGCCGCTTCAGCAGACCGAGCACGAGATCCACACCTCCGCCGCGCCGGACGCCGTGTTCGCCGTGCTGGCCGACGCACGGGCCTGGCCCGCCGTGTTCCCGCCCAGTGTCCACGTCGAACAGGTCGAGCACACCGGCTCCAGCGAGCGCATCCGCATCTGGGCCACCGCCAACGGCTCGCTGCGCACCTGGACGTCGCGGCGCGAGCTCGACGAGCGGGCCCGGCGCATCCGTTTCCGGCAGGAGGTGTCCGCCCATCCCGTCGCCGCCATGGGCGGCGAATGGATCGTCGAGGAAGCCGGCGACGGCGGCACCCGGGTGCGGCTGACGCACGACTTCCGGGCCGTGGACGACGACCCGGAGACGATCGGCTGGATCCACCGGGCCGTGGACCGCAACAGCGAAGCGGAACTGGCGTCCCTGCGCACCGCGCTGGAACGACCCGACGGCACCGCGCCGACGACCTTCGAGGACACCGTCGTCGTCCGCGGCCGTGCCGAGGACGTCTACGACTTCCTCCACCGCAGCGACCTCTGGAAGAAGCGGCTCTCCCACGTCGCGCGGATCGCGGTCAAGGAGGAGGAACCGGGGCTCCAGCACATGGAGATGGACACCCTCACCGCGGACGGCTCGGTGCACACCACCGCGTCGGTGCGAGTGTGCTTCCCCGAACGCCGCGTCATCGTCTACAAGCAGCTGCGCACGCCGCCGCTGCTCGCGCTCCATCTCGGCCGTTGGTCGGTCCGTCCCGCCGACGACGGGGACGGGATCGCCGTCACGTCGGCCCACACCGTGTCCGTGGCCCGCTCGGCGATCCCCGGCGTCCTCGGTGCGGGGGCGAGTGAGACGGACGCCGTGGACTTCGTCCGCCGGGCCCTGGGCCGCAACAGTCTGCTGACCCTGGAAGCGGCCAGGCAGTACGCCGAGTCCAGCGCCTGA	MSELPLQQTEHEIHTSAAPDAVFAVLADARAWPAVFPPSVHVEQVEHTGSSERIRIWATANGSLRTWTSRRELDERARRIRFRQEVSAHPVAAMGGEWIVEEAGDGGTRVRLTHDFRAVDDDPETIGWIHRAVDRNSEAELASLRTALERPDGTAPTTFEDTVVVRGRAEDVYDFLHRSDLWKKRLSHVARIAVKEEEPGLQHMEMDTLTADGSVHTTASVRVCFPERRVIVYKQLRTPPLLALHLGRWSVRPADDGDGIAVTSAHTVSVARSAIPGVLGAGASETDAVDFVRRALGRNSLLTLEAARQYAESSA	MKPVAMTLLALALSGCSLAPTHERPAAPVPAQYDTPAQPGQAAAPQDWRAYFNDPALQAWIAAALANNRDLRVAALRIEEARALYGVQQSERLPAIDASGEFSRGRATEPGQPRTPVSNRYRAAVGITAFELDFFGRVRSLSDAALARYLASEEAHRAATLALVAETATAYFNQRSLAEQLRLTDDTLALRETTLKLTQRRYDAGLETAIGLRTAQMLVESSRATRAELTREASLARHALGLLAGDFALPLGVDPTPLESQSLTPLAAGLPSELLTRRPDLRQAEQALRAANADIGAARAAFFPSVQLTTDIGTTADRFSDLFSGGTGGWSFAPRLTLPIFNAGRNRANLSLAETRKHIAVAQYEGSIQAAFRDVADALSARDALRDQIEAQRKVRDADRERQRLAERRYARGVANYLEMLEAQRSLFESEQEFIRLQQRRLVNAVDLYKALGGWDDGSSPAS	68.03	gnl|BL_ORD_ID|2408|hsp_num:0	2796			135	231	erythromycin; cefepime
BGC0000218.1|Doxorubicin_4 # 2872 # 3261 # 1 # ID=1_4;partial=00;start_type=ATG;rbs_motif=GGAG/GAGG;rbs_spacer=5-10bp;gc_cont=0.728	BGC0000218.1|Doxorubicin_4 	2872	3261	+	Loose	500	25.7942	OXA-55	34.48	3001813	protein homolog model	n/a	n/a	carbapenem; cephalosporin; penam	antibiotic inactivation	OXA beta-lactamase	ATGCCACAGCCAGAACCGAACGACGCCGGCTCCGGGTCGGTGACGTTCGTCAACCGATTCACCCTGAGCGGATCCGCCGAGGACTTCGAGGCGGCGTTCGCCGAAACGGCCGAGTTCCTGTGTCGCCGGCCCGGCTTCCGCTGGCACGCCCTGCTGGTGCCGGCCGACACCGGTCCCGGCTCGGCGGACGCCCGCCCGCAGTACGTGAACATCGCGGTCTGGGACGACGAGGCCTCCTTCCGCGCCGCCGTGGCACACCCGGAGTTCCCGGCCCACGCGGCCGCCCTTCGGGCCCTGAGCACCAGCGAACCGACCCTGTACCGGCACCGTCAGATCCGTGTCGCGCCGGACGTCCCGGCCGTGAGCGGGCCCGGAGGGCGGACGACGTGA	MPQPEPNDAGSGSVTFVNRFTLSGSAEDFEAAFAETAEFLCRRPGFRWHALLVPADTGPGSADARPQYVNIAVWDDEASFRAAVAHPEFPAHAAALRALSTSEPTLYRHRQIRVAPDVPAVSGPGGRTT	MNKGLHRKRLSKRLLLPMLLCLLAQQTQAVAAEQTKVSDVCSEVTAEGWQEVRRWDKLFESAGVKGSLLLWDQKRSLGLSNNLSRAAEGFIPASTFKLPSSLIALETGAVRDETSRFSWDGKVREIAVWNRDQSFRTAMKYSVVPVYQQLAREIGPKVMAAMVRQLEYGNQDIGGQADSFWLDGQLRITAFQQVDFLRQLHDNKLPVSERSQRIVKQMMLTEASTDYIIRAKTGYGVRRTPAIGWWVGWLELDDNTVYFAVNLDLASASQLPLRQQLVKQVLKQEQLLP	44.64	gnl|BL_ORD_ID|1154|hsp_num:0	1258			375	462	cloxacillin; oxacillin; cefalotin
BGC0000218.1|Doxorubicin_5 # 3258 # 4517 # 1 # ID=1_5;partial=00;start_type=GTG;rbs_motif=GGAGG;rbs_spacer=5-10bp;gc_cont=0.713	BGC0000218.1|Doxorubicin_5 	3258	4517	+	Loose	750	214.157	Mycobacterium tuberculosis kasA mutant conferring resistance to isoniazid	36.02	3003463	protein variant model	R121K, F413L	A32V:5759, S43A:5759	isoniazid-like antibiotic	antibiotic target alteration	antibiotic resistant kasA	GTGAACCGGCGGATCGTCATCACCGGGATCGGCGTGGTGGCTCCCGGCGCCGTCGGGACCAAGCCGTTCTGGGAGCTGCTGCTGTCCGGAACCACCGCCACCCGCGCCATCAGCACTTTCGACGCCACGCCCTTCCGTTCCCGTATCGCCGCCGAGTGCGACTTCGATCCGGTGGCGGCGGGGCTGTCCGCGGAGCAGGCCCGGCGCCTCGACCGGGCCGGGCAGTTCGCGCTGGTCGCCGGTCAGGAGGCGCTCGCCGACAGCGGGCTGCGAATCGATGAGGACTCCGCGCACCGGGTCGGGGTGTGCGTGGGCACCGCCGTCGGCTGCACGCAGAAACTGGAGTCCGAGTACGTCGCTCTCAGCGCGGGCGGAGCGCACTGGGTCGTGGACCCCGGCCGGGGGTCGCCCGAGCTGTACGACTACTTCGTGCCGAGTTCCCTCGCCGCCGAAGTGGCCTGGCTCGCCGGGGCGGAGGGGCCCGTGAACATCGTCTCGGCCGGGTGCACCTCGGGGATCGACTCCATCGGGTACGCCTGCGAGCTCATCCGCGAGGGGACGGTGGACGCCATGGTCGCGGGAGGCGTGGACGCACCCATCGCGCCGATCACGGTGGCCTGCTTCGACGCCATCAGGGCGACCTCCGACCACAACGACACCCCCGAGACCGCCTCGCGTCCCTTCAGCCGCAGCCGCAACGGCTTTGTGCTGGGCGAGGGCGGTGCGATCGTGGTCCTGGAAGAGGCGGAGGCGGCCGTGCGCAGGGGCGCGCGGATCTACGCCGAGATCGGCGGGTACGCCTCACGCGGCAACGCGTACCACATGACCGGGCTGCGCGCAGACGGCGCCGAGATGGCGGCGGCGATCACCGCGGCCCTCGACGAGGCCCGCCGCGACCCCTCGGACGTGGACTACGTCAACGCCCACGGAACGGCGACGAAGCAGAACGACCGGCACGAGACCTCCGCGTTCAAGCGCTCCCTGGGGGAGCACGCGTACCGGGTGCCCATCAGCTCCATCAAGTCGATGATCGGTCACTCCCTGGGCGCTGTCGGCTCGCTCGAAGTGGCGGCGACCGCACTGGCCGTGGAGTACGGGGTGATCCCGCCGACCGCGAATCTGCACGACCCGGATCCGGAACTCGACCTGGACTACGTGCCGCTGACGGCACGAGAAAAGCGGGTGCGGCACGCGCTGACGGTGGGCAGCGGCTTCGGCGGCTTCCAGAGCGCCATGCTGCTGAGCCGTCTCGAGAGGTGA	MNRRIVITGIGVVAPGAVGTKPFWELLLSGTTATRAISTFDATPFRSRIAAECDFDPVAAGLSAEQARRLDRAGQFALVAGQEALADSGLRIDEDSAHRVGVCVGTAVGCTQKLESEYVALSAGGAHWVVDPGRGSPELYDYFVPSSLAAEVAWLAGAEGPVNIVSAGCTSGIDSIGYACELIREGTVDAMVAGGVDAPIAPITVACFDAIRATSDHNDTPETASRPFSRSRNGFVLGEGGAIVVLEEAEAAVRRGARIYAEIGGYASRGNAYHMTGLRADGAEMAAAITAALDEARRDPSDVDYVNAHGTATKQNDRHETSAFKRSLGEHAYRVPISSIKSMIGHSLGAVGSLEVAATALAVEYGVIPPTANLHDPDPELDLDYVPLTAREKRVRHALTVGSGFGGFQSAMLLSRLER	MSQPSTANGGFPSVVVTAVTATTSISPDIESTWKGLLAGESGIHALEDEFVTKWDLAVKIGGHLKDPVDSHMGRLDMRRMSYVQRMGKLLGGQLWESAGSPEVDPDRFAVVVGTGLGGAERIVESYDLMNAGGPRKVSPLAVQMIMPNGAAAVIGLQLGARAGVMTPVSACSSGSEAIAHAWRQIVMGDADVAVCGGVEGPIEALPIAAFSMMRAMSTRNDEPERASRPFDKDRDGFVFGEAGALMLIETEEHAKARGAKPLARLLGAGITSDAFHMVAPAADGVRAGRAMTRSLELAGLSPADIDHVNAHGTATPIGDAAEANAIRVAGCDQAAVYAPKSALGHSIGAVGALESVLTVLTLRDGVIPPTLNYETPDPEIDLDVVAGEPRYGDYRYAVNNSFGFGGHNVALAFGRY	100.72	gnl|BL_ORD_ID|1968|hsp_num:0	1943			96	1245	isoniazid
BGC0000218.1|Doxorubicin_6 # 4523 # 5800 # 1 # ID=1_6;partial=00;start_type=ATG;rbs_motif=GGAG/GAGG;rbs_spacer=5-10bp;gc_cont=0.751	BGC0000218.1|Doxorubicin_6 	4523	5800	+	Loose	500	26.1794	PEDO-2	35.71	3003714	protein homolog model	n/a	n/a	carbapenem	antibiotic inactivation	subclass B3 PEDO beta-lactamase	ATGACAGGTACCGCGGCACGGACCGCGTCTTCGCAGCTCCACGCATCGCCCGCGGGCCGACGGGGCCTCAGGGGCCGCGCGGTGGTGACGGGTCTCGGGATCGTCGCCCCCAACGGGCTGGGGGTGGGCGCGTATTGGGACGCCGTCCTGAACGGCCGCAACGGCATCGGACCGCTGCGGCGGTTCACCGGCGACGGCCGCCTGGGCCGGCTGGCCGGTGAGGTGAGCGACTTCGTCCCCGAGGACCATCTGCCGAAGCGGCTGCTGGCGCAGACCGATCCGATGACCCAGTACGCGCTGGCCGCCGCGGAGTGGGCCCTGCGGGAGTCCGGCTGCTCCCCGTCCTCGCCGCTGGAGGCGGGGGTGATCACGGCCAGCGCGTCCGGCGGCTTCGCCTTCGGCCAGCGGGAGTTGCAGAATCTTTGGAGCAAGGGACCGGCCCACGTCAGCGCCTACATGTCGTTCGCCTGGTTCTACGCCGTCAACACCGGGCAGATCGCCATCCGGCACGATCTGCGCGGCCCGGTCGGCGTGGTGGTGGCCGAGCAGGCGGGCGGCCTCGACGCCCTCGCCCACGCTCGCCGCAAGGTCCGGGGCGGAGCCGAGCTGATCGTCTCGGGCGCCGTGGACTCGTCGCTGTGCCCGTACGGCATGGCGGCCCAGGTGAAGTCCGGCCGGCTGAGCGGCTCGGACAACCCGACAGCCGGGTATCTGCCGTTCGACCGGCGGGCGGCCGGACATGTGCCCGGCGAGGGAGGCGCGATCCTCACCGTCGAGGACGCGGAGCGGGCCGCCGAGCGGGGCGCGAAAGTGTACGGGTCGATCGCCGGGTACGGCGCGAGCTTCGACCCGCCGCCCGGCTCCGGCCGCCCCTCCGCCCTCGCCCGTGCCGTCGAGACGGCGCTGGCCGACGCCGGGCTGGACGGCTCCGACATAGCCGTGGTGTTCGCCGACGGCGCGGCCGTCCCCGAACTGGACGCAGCCGAGGCGGAGGCTCTGGCGTCGGTCTTCGGGCCGCGCCGGGTCCCGGTGACCGTCCCCAAGACTCTCACCGGCCGGCTGTATTCGGGCGCCGGGCCGCTGGACGTGGCGACCGCGCTGCTGGCGCTGCGGGACGAGGTGGTCCCGGCGACCGCCCACGTCGACCCCGACCCGGACCTGCCGCTCGACGTGGTGACCGGGCGGCCCCGGTCCCTGGCCGACGCCAGGGCGGCCCTCCTCGTCGCCCGCGGCTACGGGGGCTTCAACAGCGCTCTGGTGGTCCGGGGGGCGGCGTGA	MTGTAARTASSQLHASPAGRRGLRGRAVVTGLGIVAPNGLGVGAYWDAVLNGRNGIGPLRRFTGDGRLGRLAGEVSDFVPEDHLPKRLLAQTDPMTQYALAAAEWALRESGCSPSSPLEAGVITASASGGFAFGQRELQNLWSKGPAHVSAYMSFAWFYAVNTGQIAIRHDLRGPVGVVVAEQAGGLDALAHARRKVRGGAELIVSGAVDSSLCPYGMAAQVKSGRLSGSDNPTAGYLPFDRRAAGHVPGEGGAILTVEDAERAAERGAKVYGSIAGYGASFDPPPGSGRPSALARAVETALADAGLDGSDIAVVFADGAAVPELDAAEAEALASVFGPRRVPVTVPKTLTGRLYSGAGPLDVATALLALRDEVVPATAHVDPDPDLPLDVVTGRPRSLADARAALLVARGYGGFNSALVVRGAA	MKKIFLMVLFSCSLLGFAQTVTEPANNPKEWSQATEPFRIAGNLYYVGTYDLASYLIVTEKGNILINTGLANSLSIIKENIKALGFDYKSIKILLLTQAHFDHLGAMSEIKKETGAKLYVDEKDADALETGGKLDYELGKYGISFKPVKPDFLLKNNDKIKLGNTTLTMLHHPGHTKGSCSFIFDTKDKNSSYKILIANMPSIIVDRKFSEIASYKDIQKDYTETFKAMKKLDFDLWVASHASQFELHDKRKSGAPYNPKIFMDKSKFFKNLEDLENIFLEKIKN	149.12	gnl|BL_ORD_ID|2026|hsp_num:0	2229			315	441	
BGC0000218.1|Doxorubicin_7 # 5797 # 6858 # 1 # ID=1_7;partial=00;start_type=GTG;rbs_motif=GGxGG;rbs_spacer=5-10bp;gc_cont=0.739	BGC0000218.1|Doxorubicin_7 	5797	6858	+	Loose	300	27.7202	dfrK	30.91	3002869	protein homolog model	n/a	n/a	diaminopyrimidine antibiotic	antibiotic target replacement	trimethoprim resistant dihydrofolate reductase dfr	GTGAGCGTGCCGCAGGGGGCGCCCGGGGACCTTTACGTGGCCGGTTGCGGCGTCTGGCTGCCCCCGCCGGTGACCACGGAACAGGCCCTGGCCGCCGGCCACTGCGACCGCAGGCTCGCCTCCTCGACGCGGATGCTGTCGGTGGCGGTCGCCGACAAGGAGACACCGGCCGAAATGGCGGCCTTGGCGGCCCAGACCGCTCTGGACCGCTCCGGCGTCGCACCGGCCCACGTCGACCTCGTCCTGCACGCCAGTCTGTACTTCCAGGGGCACCATCTGTGGGCTCCCTCCTCCTACGTCCAGCGGGTGGCCGTCGGGAACCGCTGCCCCGCCATGGAGGTGCGGCAGGTGTCCAACGGCGGCATGGCCGCCCTGGAACTGGCCCGCGCGTACCTGCTTGCCGCCCCGGACCGGGTGGCCGCTCTCATCACGACAGGCGACCGGATGCATCCGCCGGGCTTCGACCGCTGGAGCAGCGACCCCGGCACGGTGTACGCCGACGGTGGTACCGCCCTCGTGCTGTCCCGGCAGGGCGGTTTCGCCCGGCTGCGCAGCCTGGTGACGGTCTCCGAACCGGTGCTGGAGGGCATGCACCGGGGCGGGCACCCGTTCGGCCCGCCGTCTCCGGAGGAGCAGCGGGCCGTGGACCTGGACGCGCACAAGCGGGCGTACGTGGCCGAGGCGGGAAGCTCGTTCAGCGTCGCCCGGGTCTCGGCGGGCCAGGAGGAGGCTCTGACCGGCGCGCTGGAGGCGGCCGGGGCCGGACTCGACGACATCAGCCGGGTCGTGCTGCCGCACATGGGGTGGCGCCGGCTGAGCGCCGCCTACTTCAACAAGTGGCACATCCAACCCGAGCGGACCACTTGGGAGTTCGGGCGGCGGACCGGCCACCTGGGGGGCGGTGACCCGATCGCCGGGTTCGACCACCTTGTGGGCTCCGGCCGCCTCGCCCCGGGGGAGCTGTGTCTGCTGGTCAGCGTCGGCGCCGGCTTCAGCTGGTCGTGCGCCGTCGTGGAGTTGCTGGAACGCCCGTCGTGGGCGGCCGCCCCGGCCGCCCGGTGA	MSVPQGAPGDLYVAGCGVWLPPPVTTEQALAAGHCDRRLASSTRMLSVAVADKETPAEMAALAAQTALDRSGVAPAHVDLVLHASLYFQGHHLWAPSSYVQRVAVGNRCPAMEVRQVSNGGMAALELARAYLLAAPDRVAALITTGDRMHPPGFDRWSSDPGTVYADGGTALVLSRQGGFARLRSLVTVSEPVLEGMHRGGHPFGPPSPEEQRAVDLDAHKRAYVAEAGSSFSVARVSAGQEEALTGALEAAGAGLDDISRVVLPHMGWRRLSAAYFNKWHIQPERTTWEFGRRTGHLGGGDPIAGFDHLVGSGRLAPGELCLLVSVGAGFSWSCAVVELLERPSWAAAPAAR	MKVSLIAAMDKNRVLGKENDIPWRIPKDWEYVKNTTKGYPIILGRKNLESIGRALPGRRNIILTRDKGFSFNGCEIVHSIEDVFEICNNEEEIFIFGGEQIYNLFLPYVEKMYITKIHYEFEGDTFFPEVNYEEWSEVSVTQGITDEKNPYTYYFHIYERKAS	216.56	gnl|BL_ORD_ID|1765|hsp_num:0	1913			84	243	trimethoprim
BGC0000218.1|Doxorubicin_8 # 6869 # 7882 # 1 # ID=1_8;partial=00;start_type=ATG;rbs_motif=AGGAG;rbs_spacer=5-10bp;gc_cont=0.747	BGC0000218.1|Doxorubicin_8 	6869	7882	+	Loose	500	25.7942	OXA-919	36.0	3006105	protein homolog model	n/a	n/a	carbapenem; cephalosporin; penam	antibiotic inactivation	OXA beta-lactamase	ATGGATGCGCCCGCGATTCTCCTGATGTTCCCCGGGCAGGGGTCCCAGCATGCGCGGATGGCCGTCGGCCTGTACGGATCCGAACCGGCCTTCACGGCCGCCATGGACGAGGTCTTCGACGCGTACGACGACGCCGGCGACAGTGAGGGCGGGCGGCTGCGTGCCGACTGGCTGAGCGACCATCCGGCCGTGCCATTGGACCACGTCACCCGGTCCCAGCCGTTGTTGTTCGCGGTGGACTACGCCCTCGGCCGGATGGTGATGGCCACGACGGGCCGGCCGTGGGCCCTGCTCGGGCACAGCGTCGGCGAAATGGCGGCGGCCGCGCTCGCCGGGGTGTTCACGCTGCGCGACGCGGCCGGCCTCCTGCTGGACCGGGTGCGACGGCTGGCCCAGGCACCGCCCGGGGGAATGCTGGCGGTCGCCGCGGCCGAGGACGTGCTGGGCCCGTATCTCGGGAATGGGGAGGTGGTGGTCGCGGCCGTCAACTCGCCCCGCCAGACCATCCTCGCCGGACCCGTCGCATCGCTCGCCGGGGTCGCCCGGGCGCTGCGGGAGGCAGGGCTTACGTGCCGTGAGGTGCCCTCGCTGACCGCCTTCCACAGTCCGATGCTGGCCCCGATCGCGGCGGGGGCGGCCGAGCGGTTCGCATCCACGCGCGTGGCGCCGTCCATCCCCCTCCGCTCCGGGTACCGGCCGGGTGCGGTGACCGGGCAACTGGCCGCCGACCCGTCGTACTGGGCCGGGCATCCCCTGGAGACGGTCCGCTTCTGGCCGGCACTGGACGCGATGCTCGGCTCCCGCACGGGCGTCGTCTGCCTGGAGACGGGGCCGGGGCAGGGGCTGAGCACCATCGCCCGCCGCCATCCGACGGTGCGGTTCGGGAAGAACTCGGTGGTGCCGCTGCTGCCGCCGCAGGCCGGCACCGCCGAGGTGGACCGGACGTCCGTGGCGGCGGCGCTGGCCGCGGTGCGCGAGCAGGGCACCGTGCTCAGTGGGCGACCCGGGCGGTGA	MDAPAILLMFPGQGSQHARMAVGLYGSEPAFTAAMDEVFDAYDDAGDSEGGRLRADWLSDHPAVPLDHVTRSQPLLFAVDYALGRMVMATTGRPWALLGHSVGEMAAAALAGVFTLRDAAGLLLDRVRRLAQAPPGGMLAVAAAEDVLGPYLGNGEVVVAAVNSPRQTILAGPVASLAGVARALREAGLTCREVPSLTAFHSPMLAPIAAGAAERFASTRVAPSIPLRSGYRPGAVTGQLAADPSYWAGHPLETVRFWPALDAMLGSRTGVVCLETGPGQGLSTIARRHPTVRFGKNSVVPLLPPQAGTAEVDRTSVAAALAAVREQGTVLSGRPGR	MQRTIKAAFGLAGGTLLAMLALQGQASAAGQKLTCMIILNANSGEVIAKEGEICDKRNSPASTFKVPLALMGFESGILKDSHNPSWPYKEGYPAWRESWKQSVDPTYWEDQSVVWFSQELTRKLGKEKFQEYTDQLNYGNRDLRGDPGKNNGMLRSWISSSLTISPNEQADFLMKMVNNKLPFSEAAMTKTMAILPSHKLSNGWTAHGKTGSAFETGPKGKPDRRRQFGWYVGWAEKGDEKVVFVRLNRNMLAHNAGMGPVTRDEQWSILEKTLK	122.55	gnl|BL_ORD_ID|4140|hsp_num:0	5210			249	324	cloxacillin; oxacillin; cefalotin
BGC0000218.1|Doxorubicin_9 # 7860 # 8720 # -1 # ID=1_9;partial=00;start_type=GTG;rbs_motif=AGGAG;rbs_spacer=5-10bp;gc_cont=0.682	BGC0000218.1|Doxorubicin_9 	7860	8720	-	Loose	500	31.187	rmtC	27.71	3000861	protein homolog model	n/a	n/a	aminoglycoside antibiotic	antibiotic target alteration	16S rRNA methyltransferase (G1405)	GTGCAGGATTCGTCCTACAAAGAGCAGGTAACTCAGGCCTTCGACCAGTCGTCGTCGACCTACGACCGACTGGGAGTGGAATTCTTCACGCCCATGGGTCGGCCCCTGGTGGAAATCTCGGAGCCGGTCACCGGTGAACGAGTGCTCGACATCGGCTGCGGGCGCGGCGCATGCCTTTTTCCGGCTGCGGAAAAGGTCGGTCCTCAGGGGCGCGTCCACGGAATCGACATTGCTCCCGGAATGATCGAGGAAGCTCGCAAGGAAGCCGCCGAACGCGGTCTGCGGAATATCGCCCTCGATGTGATGGACGCGGAGACGCCCGAACTCCCGGCGCGCTCCTTCGACCTGGTCATGGGGAGCTACAGCGTCATCTTCCTGCCGGACGCGGTGGGGGCGCTGGCGCGCTACGCCGGAATCCTGGACCACGGCGGCAGGATCGCGTTCACCAGCCCGGTCTTCCGCGCCGGCACGTTCCCGTTCCTGCCACCGGAGTTCACCCCGCTCATCCCGCAGGCGCTGCTGGAGCACCTGCCCGAGCAGTGGCGGCCCGAGGCGCTGGTCCGGCGGTTCAACAGCTGGCTGGAGCGGGCCGAGGATCTCCTCCGCACCCTGGAACGCTGCGGCTACACCTCGGTCGCCGTCACCGACGAGCCGGTGCGGATGACGGCCCTGTCCAGCGAGGCGTGGGTGGACTGGTCCCACACCCAGGGCATGCGTCTGCTGTGGCAGAACCTCCCGCAGGCCCAGCGAACGGAACTGCGCGCACGGCTCGTCGAGGGACTCGACAAGCTGAGCGACGCCACCGGGGCCCTCGCCATCGACGTGCCCGTCCGCTTCGTCACCGCCCGGGTCGCCCACTGA	MQDSSYKEQVTQAFDQSSSTYDRLGVEFFTPMGRPLVEISEPVTGERVLDIGCGRGACLFPAAEKVGPQGRVHGIDIAPGMIEEARKEAAERGLRNIALDVMDAETPELPARSFDLVMGSYSVIFLPDAVGALARYAGILDHGGRIAFTSPVFRAGTFPFLPPEFTPLIPQALLEHLPEQWRPEALVRRFNSWLERAEDLLRTLERCGYTSVAVTDEPVRMTALSSEAWVDWSHTQGMRLLWQNLPQAQRTELRARLVEGLDKLSDATGALAIDVPVRFVTARVAH	MKTNDNYIEEVTAKVLTSGKYSTLYPPTVRRVTERLFDRYPPKQLEKEVRKKLHQAYGAYIGGIDGKRLEKKIEKIIHEIPNPTTDEATRTEWEKEICLKILNLHTSTNERTVAYDELYQKIFEVTGVPTSITDAGCALNPFSFPFFTEAGMLGQYIGFDLDKGMIEAIEHSLRTLNAPEGIVVKQGDILSDPSGESDLLLMFKLYTLLDRQEEASGLKILQEWKYKNAVISFPIKTISGRDVGMEENYTVKFENDLVGSDLRIMQKLKLGNEMYFIVSRL	101.78	gnl|BL_ORD_ID|1417|hsp_num:0	1540			324	528	dibekacin; amikacin; gentamicin C; sisomicin; netilmicin; kanamycin A; tobramycin; isepamicin; G418; arbekacin; gentamicin B; gentamicin
